|
1）Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkinʼs disease and a subset of normal lymphoid cells. Nature. 1982; 299: 65-7
|
|
|
|
2）Durkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkinʼs disease. Cell. 1992; 68: 421-7
|
|
|
|
|
|
3）Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkinʼs disease. Cancer Res. 2002; 62: 3736-42
|
|
|
|
|
|
4）Bowen MA, Olsen KJ, Cheng L, et al. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J Immunol. 1993; 151: 5896-906
|
|
|
|
|
|
5）Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30＋ hematologic malignancies. Blood. 2008; 111: 1848-54
|
|
|
|
|
|
6）Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009; 146: 171-9
|
|
|
|
|
|
7）Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkinʼs lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc gammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010; 21: 2246-54
|
|
|
|
|
|
8）Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkinʼs lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007; 25: 2764-9
|
|
|
|
|
|
9）Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkinʼs lymphoma. N Engl J Med. 2010; 363: 640-52
|
|
|
|
|
|
10）Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkinʼs disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992; 327: 1478-84
|
|
|
|
|
|
11）Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013; 31: 684-91
|
|
|
|
|
|
12）Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkinʼs disease: a randomised trial. Lancet. 2002; 359: 2065-71
|
|
|
|
|
|
13）Martinez C, Canals C, Alessandrino E, et al. Relapse of Hodgkinʼs lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. ASCO Meeting Abstracts. 2010; 28(15 suppl): 8060
|
|
|
|
|
|
14）Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkinʼs lymphoma. J Clin Oncol. 2012; 30: 2183-9
|
|
|
|
|
|
15）Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012; 119: 6379-81
|
|
|
|
|
|
16）Gopal AK, Ramchandren R, OʼConnor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012; 120: 560-8
|
|
|
|
|
|
17）Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006; 134: 202-7
|
|
|
|
|
|
18）Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001; 19: 3766-70
|
|
|
|
|
|
19）Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190-6
|
|
|
|
|
|
20）Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkinʼs lymphoma: a phase 1, open-label, dose-escalation study. The Lancet Oncology. 2013; 14: 1348-56
|
|
|
|
|